Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
57 hedge funds and large institutions have $282M invested in Pardes Biosciences, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 5 closing their positions.
320% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 5
39% more funds holding
Funds holding: 41 → 57 (+16)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
51% less capital invested
Capital invested by funds: $573M → $282M (-$291M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$30M |
| 2 |
Goldman Sachs
New York
|
+$20.8M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$12.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.7M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$40.2M |
| 2 |
JCM
JS Capital Management
New York
|
-$16.4M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| $13K | +$17.9K | +1,823 | New |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $10K | +$10.9K | +1,112 | +396% |
|
|
APA
53
American Portfolios Advisors
Holbrook,
New York
| $7.22K | – | – | – |
|
54
National Bank of Canada
Montreal,
Quebec, Canada
| $7K | – | – | – |
|
|
OCM
55
Ovata Capital Management
Hong Kong
| $4K | +$4.92K | +500 | New |
|
56
Wells Fargo
San Francisco,
California
| $2K | -$186K | -18,944 | -98% |
|
57
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
FM
58
Frazier Management
Seattle,
Washington
| – | -$40.2M | -2,457,507 | Closed |
|
|
JCM
59
JS Capital Management
New York
| – | -$16.4M | -1,000,000 | Closed |
|
|
60
Citadel Advisors
Miami,
Florida
| – | -$4.91M | -300,000 | Closed |
|
|
HF
61
HRT Financial
New York
| – | -$1.15M | -69,962 | Closed |
|
|
PHK
62
Point72 Hong Kong
Hong Kong
| – | -$1K | -34 | Closed |
|
PRDS Hedge Fund Activity: Q1 2022 in Review
57 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q1 2022, worth a combined $282M — down 51% from $573M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PRDS positions and 5 closed out — a net gain of 16 holders — while 13 added to existing stakes and 13 trimmed.
The largest buyer was RA Capital Management, adding an estimated $30M. The largest seller was Frazier Management, exiting entirely with an estimated $40.2M sold.
- 57 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q1 2022, up from 41 in Q4 2021.
- Funds reported $282M of Pardes Biosciences, Inc. Common Stock stock for Q1 2022, down 51% quarter-over-quarter.
- 21 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of +16 holders.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q1 2022 was RA Capital Management, an estimated $30M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q1 2022 was Frazier Management, an estimated $40.2M sold.
Based on aggregated 13F filings for Q1 2022.